Latvia vs Low & middle income: Immunization, Hib3
Latvia
97.0%
in 2024
Low & middle income
75.7%
in 2024
Latvia rank
29th
Low & middle income rank
29th
Immunization, Hib3 over time
- Latvia
- Low & middle income
How they compare
Latvia currently reports 97.0% against 75.7% in Low & middle income, a difference of 21.3%.
That makes Latvia's figure about 1.3 times Low & middle income's.
Across all 31 years both countries report, Latvia has been ahead every year.
Latvia ranks 29th and Low & middle income ranks 29th of 191 countries.
Latvia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Latvia | Low & middle income | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 48.8% | 0.4% | 48.4% | Latvia |
| 2000s | 92.1% | 15.3% | 76.8% | Latvia |
| 2010s | 94.2% | 55.3% | 38.9% | Latvia |
| 2020s | 96.4% | 72.8% | 23.6% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Latvia or Low & middle income?
- Latvia, at 97.0% against 75.7% in Low & middle income as of 2024.
- What is the difference in immunization, hib3 between Latvia and Low & middle income?
- 21.3%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Low & middle income?
- 31 years are reported by both, from 1994 to 2024.
- How do Latvia and Low & middle income rank globally for immunization, hib3?
- Latvia ranks 29th and Low & middle income ranks 29th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.